Preferred Label : niraparib;
MeSH note : structure in first source;
CISMeF synonym : MK 4827;
MeSH synonym : 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;
MeSH hyponym : MK4827; MK-4827;
MeSH Related Number : L4JFC1PHCI;
Is substance : O;
UNII : HMC2H89N35;
Origin ID : C545685;
UMLS CUI : C2744440;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH indexing information
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
https://ansm.sante.fr/tableau-acces-derogatoire/niraparib-acetate-dabiraterone
2024
false
false
false
France
French
summary of product characteristics
package leaflet
drug combinations
administration, oral
Abiraterone Acetate/Niraparib
Abiraterone Acetate
niraparib
antineoplastic agents
guidelines for drug use
antineoplastic combined chemotherapy protocols
metastatic castration resistant prostate cancer
prostatic neoplasms, Castration-Resistant
niraparib and abiraterone
---
https://recalls-rappels.canada.ca/fr/avis-rappel/zejula-niraparib-mise-jour-sur-traitement-entretien-deuxieme-intention-ou-ulterieur
2023
false
false
false
Canada
French
English
drug information
niraparib
---
https://www.has-sante.fr/jcms/p_3456506/fr/zejula-niraparib-cancer-de-l-ovaire
2023
false
false
false
France
niraparib
treatment outcome
insurance, health, reimbursement
administration, oral
tablets
Carcinoma, Ovarian Epithelial
advanced primary peritoneal cancer
fallopian tube neoplasms
peritoneal neoplasms
high grade serous epithelial ovarian cancer
Serous Tubal Intraepithelial Carcinoma
Recurrent Platinum-Sensitive Primary Peritoneal Carcinoma
evaluation of the transparency committee
niraparib
---
https://www.ema.europa.eu/en/medicines/human/EPAR/akeega
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
drug approval
europe
Abiraterone Acetate/Niraparib
Abiraterone Acetate/Niraparib
Abiraterone Acetate
Abiraterone Acetate
niraparib
niraparib
antineoplastic agents
antineoplastic agents
neoplasm metastasis
prostatic neoplasms, Castration-Resistant
metastatic castration resistant prostate cancer
prostatic neoplasms, Castration-Resistant
adult
drug therapy, combination
prednisone
BRCA1 Gene Mutation
BRCA2 Gene Mutation
administration, oral
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Poly (ADP-Ribose) Polymerase-1
PARP2 protein, human
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Enzyme Inhibitors
steroid 17-alpha-hydroxylase
drug interactions
fertility
pregnancy
breast feeding
niraparib and abiraterone
drug evaluation, preclinical
metastatic castration-resistant prostate cancer and BRCA 1/2 mutations in whom chemotherapy
is not clinically indicated
---
https://www.has-sante.fr/jcms/p_3421297/fr/niraparib/acetate-d-abiraterone-janssen-cilag-cancer-de-la-prostate
2023
false
false
false
France
Abiraterone Acetate
insurance, health, reimbursement
drug combinations
antineoplastic agents
niraparib
Abiraterone Acetate/Niraparib
drug therapy, combination
prednisone
prednisolone
adult
neoplasm metastasis
metastatic castration resistant prostate cancer
BRCA1 Gene Mutation
BRCA2 Gene Mutation
prostatic neoplasms, Castration-Resistant
niraparib and abiraterone
evaluation of the transparency committee
prostatic neoplasms, Castration-Resistant
---
https://www.has-sante.fr/jcms/p_3477883/fr/akeega-niraparib/-acetate-d-abiraterone-cancer-de-la-prostate
2023
false
false
false
France
niraparib and abiraterone
insurance, health, reimbursement
treatment outcome
niraparib
drug combinations
Poly(ADP-ribose) Polymerase Inhibitors
antineoplastic agents
antineoplastic combined chemotherapy protocols
metastatic castration-resistant prostate cancer and BRCA 1/2 mutations in whom chemotherapy
is not clinically indicated
neoplasm metastasis
administration, oral
evaluation of the transparency committee
Abiraterone Acetate
prostatic neoplasms
---
https://www.e-cancer.fr/content/download/443876/6711321/file/MEP_INCA_RecoInhibiteursPARP_vdef.pdf
2022
France
practice guideline
talazoparib
olaparib
Poly(ADP-ribose) Polymerase Inhibitors
talazoparib
rucaparib
olaparib
niraparib
niraparib
olaparib
rucaparib
---
https://www.has-sante.fr/jcms/p_3243403/fr/zejula
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Niraparib Tosylate Monohydrate
niraparib
Poly(ADP-ribose) Polymerase Inhibitors
niraparib
administration, oral
adult
Carcinoma, Ovarian Epithelial
fallopian tube neoplasms
peritoneal neoplasms
Fallopian Tube Carcinoma
Peritoneal carcinoma
evaluation of the transparency committee
indazoles
piperidines
---
https://www.has-sante.fr/portail/jcms/c_2867845/fr/zejula
https://www.has-sante.fr/portail/jcms/c_2867845/fr/zejula-niraparib-inhibiteur-de-parp-poly-adp-ribose-polymerase
2018
false
false
false
France
French
treatment outcome
orphan drug production
adult
ovarian neoplasms
neoplasm recurrence, local
Maintenance Therapy
administration, oral
Poly(ADP-ribose) Polymerase Inhibitors
drug interactions
Poly (ADP-Ribose) Polymerase-1
PARP2 protein, human
fallopian tube neoplasms
peritoneal neoplasms
Advanced Malignant Neoplasm
niraparib
evaluation of the transparency committee
guidelines for drug use
niraparib
indazoles
piperidines
neoplasms, glandular and epithelial
Poly(ADP-ribose) polymerases
Carcinoma, Ovarian Epithelial
---
https://ansm.sante.fr/tableau-atu-rtu/niraparib-tesaro-100-nbsp-mg-gelule
2018
false
false
false
France
French
drug information
niraparib
capsules
niraparib
indazoles
piperidines
---
https://www.ema.europa.eu/medicines/human/EPAR/Zejula
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
niraparib
drug approval
europe
treatment outcome
product surveillance, postmarketing
orphan drug production
adult
ovarian neoplasms
neoplasm recurrence, local
Maintenance Therapy
administration, oral
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
drug interactions
pregnancy
breast feeding
fertility
drug evaluation, preclinical
Poly (ADP-Ribose) Polymerase-1
PARP2 protein, human
fallopian tube neoplasms
peritoneal neoplasms
Advanced Malignant Neoplasm
Progression-Free survival
niraparib
niraparib
indazoles
piperidines
disease-free survival
indazoles
piperidines
Poly(ADP-ribose) polymerases
neoplasms, glandular and epithelial
Carcinoma, Ovarian Epithelial
---
